http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Aug 2026 06:49:29 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/ArriVent+BioPharma+%28AVBP%29+PT+Raised+to+%2447+at+H.C.+Wainwright/26934554.html (Updated - August 17, 2026 6:49 AM EDT) <p>H.C. Wainwright analyst Robert Burns raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $47.00 (from $44.00) while maintaining a Buy rating.</p><p>The analyst commented: "The next key potential value inflection point for ArriVent is the expected top-line data readout in 2H26 from the Phase 3 FURVENT trial (NCT05607550), which is comparing firmonertinib against platinum-based chemo + pemetrexed in 1L EGFR ex20ins+ NSCLC patients. Per management, FURVENT is powered to detect a three-month mPFS difference between firmonertinib and the control arm, with the expectation that firmonertinib and the control arm will achieve an http://www.streetinsider.com/Analyst+PT+Change/ArriVent+BioPharma+%28AVBP%29+PT+Raised+to+%2447+at+H.C.+Wainwright/26934554.html Mon, 17 Aug 2026 06:49:29 -0400 AVBP http://www.streetinsider.com/Analyst+Comments/ArriVent+BioPharma+%28AVBP%29+PT+Raised+to+%2447+at+H.C.+Wainwright/26934554.html (Updated - August 17, 2026 6:49 AM EDT) <p>H.C. Wainwright analyst Robert Burns raised the price target on ArriVent BioPharma (NASDAQ: AVBP) to $47.00 (from $44.00) while maintaining a Buy rating.</p><p>The analyst commented: "The next key potential value inflection point for ArriVent is the expected top-line data readout in 2H26 from the Phase 3 FURVENT trial (NCT05607550), which is comparing firmonertinib against platinum-based chemo + pemetrexed in 1L EGFR ex20ins+ NSCLC patients. Per management, FURVENT is powered to detect a three-month mPFS difference between firmonertinib and the control arm, with the expectation that firmonertinib and the control arm will achieve an http://www.streetinsider.com/Analyst+Comments/ArriVent+BioPharma+%28AVBP%29+PT+Raised+to+%2447+at+H.C.+Wainwright/26934554.html Mon, 17 Aug 2026 06:49:29 -0400 AVBP http://www.streetinsider.com/Analyst+PT+Change/Citi+cuts+ArriVent+BioPharma+price+target+to+%2440/26915830.html <p>Citi analyst Yigal Nochomovitz lowered his price target on ArriVent BioPharma (NASDAQ: AVBP) to $40 from $43, while maintaining a Buy rating, according to a research note.</p><p>The revision follows ArriVent's updated timeline for its global Phase 3 FURVENT study in first-line exon 20, which is now expected to read out in the second half of 2026, compared to a prior estimate of mid-2026. This marks the second time the company has pushed out the FURVENT progression-free survival readout, with the first delay occurring in March 2026.</p><p>The analyst noted that management remains blinded to the data, but external trial monitors indicated http://www.streetinsider.com/Analyst+PT+Change/Citi+cuts+ArriVent+BioPharma+price+target+to+%2440/26915830.html Thu, 13 Aug 2026 06:12:47 -0400 AVBP http://www.streetinsider.com/Earnings/ArriVent+BioPharma%2C+Inc.+%28AVBP%29+Misses+Q2+EPS+by+13c/26914391.html <p>ArriVent BioPharma, Inc. (NASDAQ: AVBP) reported Q2 EPS of ($1.05), $0.13 worse than the analyst estimate of ($0.92).</p><p>For earnings history and earnings-related data on ArriVent BioPharma, Inc. (AVBP) <a href="http://www.streetinsider.com/ec_earnings.php?q=AVBP">click here</a>.</p> http://www.streetinsider.com/Earnings/ArriVent+BioPharma%2C+Inc.+%28AVBP%29+Misses+Q2+EPS+by+13c/26914391.html Wed, 12 Aug 2026 17:24:51 -0400 AVBP http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ArriVent+BioPharma%2C+Inc.++For%3A+Jun+30/26913252.html si-local-file:///var/storage/secattach/20260812/26913252.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ArriVent+BioPharma%2C+Inc.++For%3A+Jun+30/26913252.html Wed, 12 Aug 2026 16:21:00 -0400 AVBP O.50783452 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ArriVent+BioPharma%2C+Inc.++For%3A+Jun+30/26913252.html si-local-file:///var/storage/secattach/20260812/26913252.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++ArriVent+BioPharma%2C+Inc.++For%3A+Jun+30/26913252.html Wed, 12 Aug 2026 16:21:00 -0400 AVBP O.50783452 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ArriVent+BioPharma%2C+Inc.++For%3A+Aug+11/26912847.html si-local-file:///var/storage/secattach/20260812/26912847.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ArriVent+BioPharma%2C+Inc.++For%3A+Aug+11/26912847.html Wed, 12 Aug 2026 16:08:00 -0400 AVBP O.50783452 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ArriVent+BioPharma%2C+Inc.++For%3A+Aug+11/26912847.html si-local-file:///var/storage/secattach/20260812/26912847.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++ArriVent+BioPharma%2C+Inc.++For%3A+Aug+11/26912847.html Wed, 12 Aug 2026 16:08:00 -0400 AVBP O.50783452 http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Press+Releases/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html <ul type="disc"><li style="margin-bottom:8pt; text-align:justify;"><em>Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization</em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial cancers expected Q3 2026 </em></li><li style="margin-bottom:8pt; text-align:justify;"><em>Cash and investments of $373.1 million as of June 30, 2026 expected to fund operations into 2028<br/></em><br/></li></ul> <p align="justify">NEWTOWN SQUARE, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), http://www.streetinsider.com/Globe+Newswire/ArriVent+BioPharma+Reports+Second+Quarter+2026+Financial+Results/26912554.html Wed, 12 Aug 2026 16:01:00 -0400 A.06822034 A.35552990 A.50216777 AVBP O.00074346 O.20026344 O.50783452 O.54516537 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ArriVent+BioPharma%2C+Inc.+++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820000.html si-local-file:///var/storage/secattach/20260727/26820000.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++ArriVent+BioPharma%2C+Inc.+++++++++++++++Filed+by%3A+BlackRock%2C+Inc./26820000.html Mon, 27 Jul 2026 16:27:00 -0400 AVBP O.50783452